US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved
Gilead Sciences
' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as
pre-exposure prophylaxis
or
PrEP
, have existed for more than a decade. But because they typically require taking a daily pill, they have yet to make a significant dent in global infections.
"This is a historic day in the decades-long fight against HIV," Gilead chairman and chief executive Daniel O'Day said in a statement.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
If You Eat Ginger Everyday for 1 Month This is What Happens
Tips and Tricks
Undo
Lenacapavir
, marketed under the brand name
Yeztugo
, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine.
The company conducted two large clinical trials. The first, involving more than 2,000 women in sub-Saharan Africa, resulted in a 100 percent reduction in infections and demonstrated superiority over the daily oral pill Truvada.
Live Events
In the second trial, involving over 2,000 men and gender-diverse individuals, only two infections were recorded - a 99.9 percent prevention rate, again surpassing Truvada.
Reported side effects included injection site reactions, headache, and nausea.
Results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 "Breakthrough of the Year."
- Price concerns dampen hope -
Despite the impressive results, optimism may be tempered by the drug's cost -- a list price of $28,218 per year in the United States, Gilead spokeswoman Blair Baumwell told AFP in an email Wednesday.
An earlier long-acting
HIV prevention
shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact.
Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually.
Baumwell said the $28,000-plus per year cost for Lenacapavir as a preventive drug is "in line with" those of existing PrEP products and that the company inspects insurers to cover it.
"We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage," she said in the email.
Activists are urging Gilead to drastically cut the price to help end the HIV pandemic.
"Even high-income countries will not be able to afford widescale use of lenacapavir at prices above US $20,000 per year," said Andrew Hill of Liverpool University, who led a team of chemists and scientists that found it could be mass-produced and sold for as little as $25 per person per year.
"I congratulate Gilead and US partners for advancing this important innovation," added Winnie Byanyima, under-secretary-general of the United Nations. "Lenacapavir could be the tool we need to bring new infections under control -- but only if it is priced affordably and made available to everyone who could benefit."
In October, Gilead signed agreements with six pharmaceutical companies to produce and distribute generic versions of the drug, pending regulatory approval, in 120 low- and middle-income countries.
Because it will take time for those countries to begin production, the company also announced a separate deal in December with the Global Fund -- an international partnership established by the United Nations, alongside the US President's Emergency Plan for AIDS Relief (PEPFAR) and others -- to purchase doses for two million people.
However, cuts to the PEPFAR program under President Donald Trump's administration have cast uncertainty over the future of that agreement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
43 minutes ago
- Time of India
Uttarakhand HC seeks affidavit on vet doctors' transfer norms
Dehradun: The division bench of Chief Justice G Narendar and Justice Alok Mahra, while hearing petitions challenging transfer regulations of veterinary doctors on Friday, directed the animal husbandry secretary to review the objections and file a report along with an affidavit within two weeks. Secretary BVRC Purushottam appeared via video conferencing as per court instructions. The court questioned the transfer process, observing discrepancies between the existing regulations and their implementation. Petitioners stated that the regulations clearly mention employees above 55 years of age or those suffering from serious health conditions should not be transferred. However, these rules were overlooked. "Staff with minor ailments like diabetes or uric acid were retained at their posts, while those with serious conditions were transferred to remote locations," the petitioners' counsel argued. The petition cited the example of Dr Ravishankar Jha, stationed in Gadarpur, who had recently undergone bypass surgery. Despite ranking 21st on the departmental transfer list, he was transferred to Narsan, Haridwar, while several others ahead of him on the list remained unaffected, violating departmental norms. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo The regulations prohibit transfers for employees above 55 years. The court stressed that illness-based transfer exemptions "should rely on annual certificates from the state medical board" to avoid misuse of medical grounds for avoiding remote postings. It advised the department to cross-check medical records against state medical board reports during transfer processes. The matter arose after several veterinary officers challenged their transfer orders, claiming a violation of rules despite their long service in difficult areas and serious health issues.
Time of India
43 minutes ago
- Time of India
Tripura CM mulls sex education in Class VIII-XII curriculum
Agartala: Tripura CM on Friday said the state govt is considering the introduction of sex education in the curriculum for students in Classes VIII to XII. Speaking at the legislative forum in the state assembly, Saha emphasised the importance of this initiative, stating, "We are considering incorporating sex education and HIV/AIDS awareness in the school curriculum in Class VIII-XII. Tired of too many ads? go ad free now This is not a matter of controversy, it is a necessity." He also encouraged community involvement, suggesting that MLAs could allocate funds to support HIV/AIDS patients. Saha highlighted the equal impact of HIV/AIDS on both boys and girls and stressed the importance of engaging youth in sports, cultural activities, and other creative pursuits to steer them away from drug addiction and reduce their vulnerability to HIV/AIDS. He said Tripura was the first state in India to introduce Red Ribbon Clubs in schools and plans to create youth ambassadors to lead campaigns against drug abuse. Expressing concern over the rising number of HIV/AIDS cases and injecting drug users, particularly among teenagers, Saha said an average of 120 new HIV infections are reported each month in the state, despite preventive efforts by the state AIDS Control Society. In response to a proposal by Congress legislator Sudip Roybarman, the chief minister supported the idea of adding a dedicated chapter on sex education and HIV/AIDS to the school curriculum to raise awareness among the most vulnerable age group. Additionally, he suggested that each MLA could allocate Rs 1 lakh per year from their area development fund for initiatives against drugs and HIV.
Time of India
an hour ago
- Time of India
AI 171 crash: 231 victims identified after DNA matching, 210 bodies handed over to kin
Ahmedabad: Until 6pm on Friday, forensics experts had identified 231 victims of the AI 171 crash after DNA cross-verification and handed over 210 bodies to their grieving families, Civil Hospital officials said. "While 10 families have informed us that they will be reaching the hospital soon to collect the mortal remains for the last rites, three bodies will be handed over only after the completion of airline transfer formalities. Eight families have at least one member identified based on DNA profiling but are awaiting identification of the others," said Dr Rakesh Joshi, Medical Superintendent of Civil Hospital, on Wednesday evening. Of the 210 bodies handed over to the families, 155 are of Indian citizens, 36 of British nationals, seven of Portuguese nationals and one Canadian national. Eleven of the deceased are non-passengers, the officials said. "Out of the Indian nationals identified so far, 60 are from Ahmedabad, 23 from Anand, 21 from Vadodara, 14 from Diu, 11 from Surat and Kheda each, nine from Mumbai and seven from Bharuch and Udaipur each," Dr Joshi said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Of the 71 patients admitted to the hospital after the crash, five are still under treatment. The majority suffered burns and fractures, hospital sources said. With about 16 bodies identified through genetic analysis in the past 24 hours, the forensic experts have entered the most challenging phase of the DNA profiling effort. Sources said the samples that remain are charred and experts are trying to extract DNA from the bone and tooth pulp tissue. They added that in most cases, the bodies are desiccated, and thus tissue cannot be used for DNA extraction. Experts said that the retrieval and matching of DNA are long processes. Even as the crowd has thinned out at Civil Hospital, teams of counsellors and govt officials are working to coordinate with the families. Sources said that in a week after the incident, most victims have been identified, and help is being extended to the families to send the mortal remains to places within or outside Gujarat.
